首页 正文

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

{{output}}
Background: Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non-small-cell lung cancer (NSCLC) in a phase 3 trial. Data are needed ... ...